The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Neoadjuvant checkpoint inhibition with radiotherapy in MSI-H/dMMR rectal cancer
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, gives an overview of the Phase II ES2201 trial (NCT04751370), which investigated neoadjuvant nivolumab plus ipilimumab combined with short course radiation in patients with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors. The primary endpoint, pathological complete response, was promising, particularly in patients who subsequently underwent surgery. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
